Processa Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Processa Pharmaceuticals, Inc. (PCSA) had Additional Paid in Capital, Common Stock of $107.11 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-14
- 2026-06-30: Additional Paid in Capital, Common Stock $107.11M.
- 2026-03-31: Additional Paid in Capital, Common Stock $106.70M.
- 2025-12-31: Additional Paid in Capital, Common Stock $106.66M.
- 2025-09-30: Additional Paid in Capital, Common Stock $103.55M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $107.11M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $106.70M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $106.66M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $103.55M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $100.39M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $93.88M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $89.22M 10-K · filed 2026-03-18 | $89.21M 10-K · filed 2025-03-20 |
| 2024-09-30 | $88.51M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $87.43M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $87.28M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $80.66M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $80.43M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $80.34M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $78.71M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $72.02M 10-K · filed 2024-03-29 | $72.02M 10-K · filed 2023-03-30 |
| 2022-09-30 | $68.77M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $65.60M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $63.59M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $62.31M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $60.85M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $59.89M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $58.83M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $48.33M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |